Klaus Okkenhaug obtained his B.Sc. in Biochemistry from the University of Victoria, British Columbia, Canada, followed by a Ph.D. in Immunology from the University of Toronto, where he studied CD28 signalling in Rob Rottapel's lab. In 1999, he moved to London, UK, where he joined Bart Vanhaesebroeck's group at the Ludwig Institute for Cancer Research as a Postdoctoral Fellow, working on the role of p110? in immune responses. Klaus joined the Laboratory of Lymphocyte Signalling and Development at the Babraham Institute as a Group Leader in 2003. His main research interests include the role of PI3K signalling in the immune system with particular focus on T-cell activation, differentiation and regulation.